Navigation Links
Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Date:1/10/2008

, it is estimated that approximately 40% of people aged 65 and above, or 16 million, have AAMI. It is characterized by gradual memory impairment (subjective memory decline and objective memory loss) with the absence of dementia. Individuals with AAMI have been shown to have a three-fold greater risk for development of dementia than individuals who do not meet AAMI criteria.

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms, a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively.

Disclosure Notice

The information contained in this document is as of January 10, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
2. Amarin to Present at 4th Annual Bio Investor Forum
3. Amarin Announces Initiation of Cardiovascular Development Strategy
4. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
5. Amarin Signs Agreement to Acquire Ester Neurosciences
6. NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... , May 21, 2013 ... Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services ... Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, ... in 2011 and is expected to grow at a ... an estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 2013 Revolutionary Science, the manufacturer of ... announced today that they have expanded their colony counter ... IncuCount, IntelliCount, InCount and ImpressCount. These affordable colony ... useful in food microbiology and pharmaceutical manufacturing. , The ... A bright white enclosure with jet black accents ...
Breaking Biology Technology:ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
... Harry Whelan has become the first Medical ... National Defense University in Washington, D.C. , ,Whelan, a professor ... has signed a two-year contract at the Center for ... from around the country receiving the appointment, he will be ...
... from Sharon Farmer. In the summer of 2001, I ... Senator John Kerry and technology executives in Silicon Valley. At ... presidential campaign, and I had no particular interest in an ... months later, I had the opportunity to interview the Senator ...
... The Croquet Project , a joint software ... (DoIT), the University of Minnesota and ... has announced the release of the Croquet developers release ... technology and peer-to-peer network architecture that supports online learning ...
Cached Biology Technology:Medical College of Wisconsin researcher gets national defense appointment 2John Kerry talks technology 2John Kerry talks technology 3John Kerry talks technology 4UW-Madison releases open 3D collaboration environment 2
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/18/2013)... (May 18, 2013) Research presented at Digestive ... digestive health through diet and lifestyle. , ... by reduced muscle strength, fatigue and poor quality ... patients are in remission. A randomized, double blind, ... vitamin D supplementation corresponded to significant relief of ...
(Date:5/17/2013)... AGA Research Foundation announced a new grant that intends ... microbiota, one of today,s most exciting areas of science, ... Research Awards Panel selected Andrew T. Chan, MD, MPH ... Medical School, Boston, as the 2013 AGA-Elsevier Gut Microbiome ... of funding, commencing in July 2013, to test the ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... This release is available in French . </P , ... have found the presence of 356 animal inclusions in completely ... used the X-rays of the European light source to image ... that allows rapid survey of large amounts of opaque amber. ...
... in Spanish . Humidity, environmental ... of the rock, etc give rise to the appearance ... dust accumulation, etc. , The treatments used up to ... almost exclusively, to preserve the beauty of the affected ...
... Science Picks, you can discover recent dramatic developments at Kilauea ... how the USGS helps forecast and notify emergency managers of ... on their way. You can also find out how the ... as you start gearing-up for baseball season, learn about the ...
Cached Biology News:Scientists discover 356 animal inclusions trapped in 100 million years old opaque amber 2New mineralogical techniques contribute to prevent national heritage damage 2New mineralogical techniques contribute to prevent national heritage damage 3USGS April 2008 science picks 2USGS April 2008 science picks 3USGS April 2008 science picks 4USGS April 2008 science picks 5USGS April 2008 science picks 6USGS April 2008 science picks 7USGS April 2008 science picks 8
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Eliminate electrical interference from any analog signal, without filtering. Ideal for electrophysiology applications like EKG, EMG, and EEGs. Removes 50/60hz noise and harmonics caused by grounding ...
... 400 Spun Columns, 10. *SizeSep 400 Spun ... 400 base pairs in length. - ... and pre-equilibrated in distilled water containing 0.15% Kathon ... ~ 400 base pairs. *Extremely useful ...
... GFX Purification Kit, 25 purifications. ... cDNA probesProvides efficient removal of unincorporated ... reactions with superior yields of labeled ... purification of cDNA labeled by either ...
Biology Products: